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1. Introduction 
Rheumatoid arthritis (RA) is a systemic, autoimmune, inflammatory disorder affecting 0.5-
1% of the North American population (Gabriel, 2001). It has a predilection for young women 
with an incidence rate of up to 130 per 100,000 compared with 70 per 100,000 in men 
[Minaur et al, 2004]. It is associated with a median survival decrease of up to 11 years 
compared to the general population (Minaur et al., 2004). The disease course may be 
complicated by extra-articular manifestations that confer an added burden of morbidity and 
mortality. RA-associated cardiovascular and infectious complications are commonly 
highlighted as major causes of morbidity and mortality in these patients (Maradit-Kremers 
et al., 2005). However, pulmonary involvement, the third leading extra-articular 
manifestation of RA, is now also recognized as a major cause of morbidity and mortality in 
RA patients. This was demonstrated in an autopsy study of 81 RA patients where the cause 
of death was determined to be infectious in 23.5%, cardiovascular in 17.3% and respiratory 
in 9.9% of patients (Suzuki et al., 1994). Pulmonary complications are the presenting 
manifestation of RA in up to 20% of patients (Brown, 2007). These complications include 
airway disease, pleural effusion, pulmonary nodules, and interstitial lung disease (ILD). 
This chapter will discuss the epidemiology, clinical features, management of RA-associated 
ILD (RA-ILD) and highlight the links between pulmonary involvement and autoimmunity. 
2. RA-ILD  
2.1 Scope and epidemiology 
Reports of the prevalence of RA-ILD are widely variable and likely comprise significant 
underestimates owing to inconsistency of clinical criteria used to define the condition, 
methods used for disease detection, and heterogeneity of study populations. Identification 
of ILD is further confounded by the fact that many of the medications used for the treatment 
of RA have potential deleterious effects on the lungs. A recent population-based study from 
the Rochester Epidemiology Project suggested that as many as 1 in 10 patients with RA will 
be diagnosed with ILD over the course of the disease (Bongartz et al., 2010).  
RA patients with extra-articular manifestations, in particular those with respiratory disease, 
are at increased mortality risk, with a standardized mortality ratio ranging from 2.5 to 5.0 
(Brown, 2007). RA-ILD remains a major cause of death in RA; the median and 5-year 
survival is 3.5 years and between 37-39%, respectively (Hakala, 1988). The mortality risk was 
found to be most significant in the first 5 years after an initial hospitalization. In a more 
recent incident-based study from the Rochester cohort of 582 patients with RA, the risk of 
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death was found to be three times higher in RA patients with ILD compared to patients 
without ILD; the median survival following ILD diagnosis was only 2.6 years (Bongartz et 
al., 2010). In general, treating connective tissue disease -associated ILD (CTD-ILD) early, 
with immunosuppressive medications, not only may halt ILD progression, but may improve 
quality of life. This may be true for RA-ILD as well, but these disease-specific data are 
scarce. The poor prognosis of RA patients with ILD highlights the need for clinicians to 
recognize the clinical features of this condition and be cognizant of its course and 
management. 
2.2 Clinical features and course 
Clinical detection of ILD in RA patients may be challenging. The challenge stems from the 
non-specific clinical features of this condition and, typically, symptoms that are often 
masked or manifest in an insidious manner. Patients most commonly present complaining 
of worsening shortness of breath on exertion and a dry cough. Since this patient population 
suffers from arthritis that often limits their physical activity, the presentation of exertional 
dyspnea may in fact already denote advanced lung disease. Moreover, since maximum 
ventilation at peak exercise is approximately 70% of maximum voluntary ventilation (MVV), 
in the absence of significant lung disease, there is significant pulmonary reserve and exercise 
should not be limited by dyspnea (Hansen et al., 1984). Therefore, a low clinical threshold of 
suspicion should be maintained with respect to complaints of dyspnea in these patients. 
Complaints of lower-extremity swelling, syncopal episodes, and exertional chest pain may 
represent an underlying pulmonary arterial hypertension with right-sided heart failure, a 
severe complication of ILD. Clinicians should also be mindful of the fact that RA patients, 
particularly elderly patients, may have other co-morbid conditions such as congestive heart 
failure or anemia that may present with similar symptoms. Therefore, clinicians must 
consider and actively search for ILD in the presence of these symptoms, rather than simply 
assigning them to other more common co-morbidities.   
Physical exam in early ILD may be normal. A small proportion of patients may have digital 
clubbing (Rajasekaran et al., 2001). Most commonly, RA patients with ILD will have bilateral 
fine crackles heard best at the end of inspiration and tend to be more prominent at the lung 
bases. Expiratory wheezing, bronchial or upper airway sounds are uncommon and their 
presence can suggest either airway disease involvement or a concomitant respiratory 
condition such as chronic obstructive pulmonary disease (COPD) or asthma. The presence 
of hypoxemia may denote a more advanced disease process. Physical exam findings of an 
elevated jugular venous pressure with CV waves, an abnormal hepatojugular reflux, and 
lower-extremity pitting edema can represent an underlying right ventricular dysfunction 
relating to pulmonary arterial hypertension. A parasternal heave, a prominent second heart 
sound, and a tricuspid regurgitation murmur on precordial exam, as well as a pulsatile liver 
and ascites on abdominal exam, are all findings suggestive of underlying advanced 
pulmonary arterial hypertension. Although uncommon in RA-ILD without concomitant 
COPD, clinicians should be aware of these physical findings to facilitate early detection of 
this serious complication. 
Evolving evidence points to the existence of another unique clinical entity of RA-associated 
ILD in which patients also present with signs and symptoms suggestive of COPD. The 
syndrome of combined pulmonary fibrosis and emphysema (CPFE) was first described by 
Cottin et al. in 2005. CPFE was characterized by the association of tobacco smoking, significant 
dyspnea, impaired diffusion capacity on pulmonary function test, exertional hypoxemia and 
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radiological features of both emphysema and diffuse interstitial lung opacities. This clinical 
entity was also described in a retrospective study of 34 patients with a connective tissue 
disease (CTD), 18 of which had RA. This study demonstrated the presence of CPFE in patients 
with CTD, particularly RA, and identified several features that distinguish CPFE in patients 
with CTD compared to non-CTD CPFE (Cottin et al., 2011). These features include a female 
predilection, younger age, higher lung volumes but a lower diffusion capacity. Smoking was 
identified in the majority of CTD patients with CPFE, but not in all. The presence of these 
features led the authors to suggest that CPFE is a unique pulmonary manifestation in patients 
with CTD, particularly RA (Cottin et al., 2011). Therefore, when assessing RA patients with 
respiratory complaints, clinicians should inquire about tobacco smoking history and be 
cognizant of CPFE features as these patients would potentially need additional monitoring 
and screening for development of pulmonary hypertension.  
RA-associated ILD is a chronic, progressive pulmonary manifestation that confers 
significant morbidity and mortality (see section 2.1). As will be described in the next section, 
RA-associated ILD is heterogeneous in its presentation, but can be further defined by its 
histologic features. The course, radiographic pattern, response to treatment, and prognosis 
of RA-ILD can be linked to the specific underlying histological pattern. 
2.3 Histopathology 
ILD is defined as varying levels of inflammation and fibrosis of the lung parenchyma 
(Cushley et al., 1999). The classification criteria for ILD has undergone revision over the past 
10 years and is still evolving as there is increased awareness that different histopathologic 
subtypes correlate with specific clinical presentations and have differing prognostic and 
therapeutic consequences. Nevertheless, it is widely accepted that ILD associated with CTD 
constitutes a unique class within the spectrum of ILD. From histological perspective, 
virtually any of the known histological patterns of interstitial pneumonia (IP) can occur in 
association with CTD. However, certain histological patterns are known to be more 
commonly associated with certain subtypes of CTD. In the case of RA, the most common 
patterns identified are the usual interstitial pneumonia (UIP) followed by the non-specific 
interstitial pneumonia (NSIP) (Lee et al., 2005). 
Infiltration of inflammatory cells (plasma cells, neutrophils, and different T cells  
subpopulations) as well as varying degrees of fibrosis of the alveolar wall can be found in 
both NSIP and UIP (Parra et al., 2007). The key differentiating histological feature between 
the two is the temporal uniformity of the lesions seen in NSIP versus the temporal 
heterogeneity found in UIP. Temporal heterogeneity refers to the presence of varying 
degrees of inflammation and fibrosis within the same diseased lung. Therefore, in UIP, areas 
of normal lung are adjacent to areas of active inflammation. There are expanding areas of 
fibrosis with fibroblastic foci at the leading edges. These fibroblastic foci are rich in dense 
collagen and proliferating fibroblasts and are considered the hallmark lesions of UIP 
(Katzenstein & Myers., 1998). Another parenchymal lesion associated with UIP is formation 
of interconnected cystic spaces, called honeycombing, which indicates end stage fibrosis 
without evidence of active inflammation. In contrast, lung tissue in NSIP typically shows a 
homogeneous pattern of lymphocytic infiltrates in the alveolar septae (Parra et al., 2007). 
These correspond with areas of ground glass attenuation on thoracic high-resolution 
computed tomography (HRCT) and are the most characteristic feature of NSIP (Katzenstein 
& Fiorelli., 1994, Travis et al., 2000). 
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RA- ILD can also infrequently present with acute interstitial pneumonia (AIP), a sub-acute 
to rapidly progressive respiratory failure, and diffuse alveolar damage (DAD). DAD is the 
histologic abnormality observed in the acute respiratory distress syndrome (ARDS), which 
may be triggered most commonly by lung infections, sepsis, drug-induced lung disease, and 
inhalational lung injury (Katzenstein et al., 1986). The term AIP is reserved for cases where 
the inciting factor is unknown. Histologically, DAD is characterized by diffuse distribution 
of a temporally homogeneous appearance with alveolar septal thickening and fibrosis 
including hyaline membrane formation (Katzenstein et al., 1986). Distinguishing AIP from 
DAD superimposed on a pre-existing ILD, such as UIP, can be technically challenging. 
Clinically, the histological findings of AIP confer a mortality risk exceeding 50%, typically 
within several months of diagnosis (Katzenstein et al., 1986; Parambil et al., 2006). Patients 
surviving the acute syndrome are commonly left with significant morbidity and are at risk 
of recurrences (Bouros et al., 2000; Vourlekis et al., 2000).  
Finally, in addition to a vigilant search for possible infectious triggers, clinicians assessing 
RA patients with respiratory symptoms should also obtain detailed medication history as 
certain medications used for the treatment of RA, such as methotrexate, cyclophosphamide, 
sulfasalazine, and TNF-alpha inhibitors have potential pneumotoxic effects and can present 
with diffuse lung disease. These medications can lead to ILD, particularly the NSIP pattern, 
but also may lead to a histologic pattern known as hypersensitivity pneumonitis (HP); thus, 
the etiology of ILD in RA can present a challenge to clinicians. Careful history regarding the 
temporal relationship between initiation of drugs and onset of respiratory symptoms may 
be helpful in deciphering causality. Onset of pulmonary findings within a 2 month period of 
drug initiation and stability in lung function and/or radiologic damage upon 
discontinuation of the toxic culprit are findings that support a drug-related etiology of ILD 
(Dixon et al., 2010). 
As an example, methotrexate, the most commonly used drug for the treatment of RA, can 
result in interstitial pneumonitis and pulmonary fibrosis at any time or dosage during the 
course of treatment (Hilliquin et al., 1996; St Clair et al., 1985; Swierkot & Szechiński 2006). 
And, while the clinical presentation may be identical to RA-ILD, methotrexate-related 
toxicity usually occurs within 6 months of initiation, often within 2-3 months, and does not 
involve progressive decline in pulmonary function test (PFT). Other clinical clues to 
methotrexate-induced ILD are fever and eosinophilia from serum or from bronchoalveolar 
lavage fluid. The histopathologic correlate of methotrexate-induced ILD may be one of HP, 
DAD or a cellular NSIP type pattern (Imokawa et al., 2000; Kremer et al., 1997; St Clair et al., 
1985). In contrast, cyclophosphamide, another agent used for the treatment of RA, is usually 
associated with an insidious onset of pulmonary symptoms and typically occurs after 
prolonged use (Segura et al., 2001). Therefore, it is essential to be vigilant regarding 
pulmonary symptoms even among patients with stable treatment and those with 
established disease. 
2.4 Evaluation and radiographic findings 
The diagnostic gold standard for identification and classification of RA-ILD has traditionally 
been a surgical, open-lung biopsy. Yet, since chest imaging now has a good correlation with 
histopathology, such a biopsy is not always necessary for diagnosis (Yoshinouchi et al., 2005). 
In fact, chest imaging is now considered a critical diagnostic and prognostic modality when 
assessing patients with suspected RA-ILD. It is foreseeable that in the future, a composite of 
www.intechopen.com
 Rheumatoid Arthritis Interstitial Lung Disease 
 
69 
radiologic and histologic data may be used to predict outcomes as it relates to RA-ILD, as this 
composite measure is now used in idiopathic pulmonary fibrosis (Raghu et al., 2011). 
The chest radiographic pattern may be a useful screening test in select cases (Gabbay et al., 
1997). Chest radiograph findings consist of a bilateral, peripheral, reticular opacity pattern 
with basal predominance. It is not possible to reliably distinguish between UIP and NSIP on 
chest radiograph. It is critical to recognize that patients with clinically important RA- ILD 
may have a completely normal chest radiograph; thus, the sensitivity of this test is 
inadequate to rule out RA-ILD. Instead, the standard of care in assessing patients with 
suspected RA-ILD is a thoracic high-resolution CT (HRCT), a method which has a very high 
sensitivity and can detect even mild disease. 
HRCT provides a non-invasive radiological characterization of lung abnormality that may 
correlate reasonably well to the underlying pathology (Lee et al., 2005; MacDonald et al., 
2001; Yoshinouchi et al., 2005). The characteristic UIP pattern on HRCT demonstrates 
marked interlobular septal thickening and intra-lobular reticulation, traction bronchiectasis 
(tethering open of otherwise relatively normal airways by the increased elasticity of 
surrounding lung) and honeycomb cysts, in a peripheral and basilar distribution 
(Macdonald et al., 2001; Martinez 2006) (See Figure 1). ‘Ground-glass’ opacities may be seen, 
but are atypical and the extent of ground glass and other atypical findings (such as upper 
lobe or central involvement) reduce the confidence that the radiologic pattern represents 
UIP (Macdonald et al., 2001, Martinez 2006).  
In contrast to UIP, NSIP usually features more prominent ‘ground-glass’ changes. The 
‘ground-glass’ changes tend to be symmetric with a basal and sub-pleural predilection. 
About half of all patients with NSIP will also have significant reticulation and a minority 
will have honeycombing (Yoshinouchi et al., 2005). Reticulation and honeycombing, when 
present in NSIP, are usually associated with the fibrosing sub-type (fibrosing NSIP) rather 
than the cellular sub-type (cellular NSIP) (See figures 2 & 3). The distinction refers to the 
histologic appearance of the lung interstitium, where the former is associated with more 
collagen deposition and the latter with more mononuclear inflammatory cellular infiltration. 
The distinction between UIP and NSIP on HRCT remains challenging in many cases, as 
demonstrated by a study of 50 patients with idiopathic ILD, where the HRCT pattern of 
NSIP was indistinguishable from UIP in 32% of patients (Hartman et al., 2000). The HRCT 
diagnosis of NSIP was found to have a sensitivity and specificity ranging from 60 to 70% 
(Hartman et al., 2000). The most distinguishing feature appeared to be the finding of more 
prominent ‘ground-glass’ changes in NSIP versus UIP (MacDonald et al., 2001). The 
radiographic appearance of AIP early in its course is quite distinct from UIP and NSIP, 
primarily by the presence of bilateral, frequently diffuse, airspace disease with air 
bronchograms. However, as AIP progresses, the airspace pattern becomes less prominent 
and instead it presents with ‘ground glass’ changes and reticular opacities, making the 
distinction between the various ILD patterns more difficult (Manjunatha et al., 2010). 
Overall, the diagnostic challenges using imaging modalities outlined so far highlight the 
underlying need of a more definitive tissue diagnosis by lung biopsy in select cases, which is 
further discussed in the next section.  
2.5 Screening and diagnosis 
The significant morbidity and mortality associated with ILD in RA patients calls for 
increased vigilance on the part of clinicians to respiratory complaints in these patients. 
Clinicians should inquire about the presence of any respiratory symptoms during both 
www.intechopen.com
 Challenges in Rheumatology  
 
70
 
 
 
A. Chest radiograph (PA view) shows bilateral, peripheral reticulation and volume loss, B&C. HRCT 
shows bilateral, peripheral reticulation, traction bronchiectasis and honeycombing, D. Surgical lung 
biopsy; low magnification (16x H&E) view of UIP with sub-pleural areas of microscopic honeycomb 
change interspersed with areas of less affected lung parenchyma, E. Surgical lung biopsy; high 
magnification (100x H&E) view showing a fibroblast focus likely representing active fibrosis. 
Fig. 1. RA-ILD UIP  
A
B 
D 
C
E
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Fig. 2. A. HRCT of cellular NSIP in RA, showing predominantly peripheral and very subtle 
ground glass opacification, B. Surgical lung biopsy from patient in panel A; cellular NSIP 
with diffuse mild interstitial chronic inflammatory infiltrates (50x, H&E), C. HRCT of 
fibrotic NSIP in RA, showing predominantly  reticulation, D. Surgical lung biopsy from 
patient in panel C;  fibrotic NSIP with diffuse alveolar septal fibrosis without architectural 
distortion or remodeling (50x, H&E). 
initial and follow-up visits, with particular emphasis on exertional dyspnea and persistent 
non-productive cough. Tobacco smoking history should be obtained from every RA patient 
and patients should be strongly encouraged to achieve smoking cessation and avoid passive 
(second-hand) smoking. A complete medication history should also be obtained to assess for 
any recent or current use of medications known to have potential pulmonary toxicity. 
In the presence of respiratory symptoms, clinicians should also assess for any occupational 
or environmental exposures as well as for infectious stigmata. Examination of the 
respiratory system should be included in the routine follow-up of RA patients, with 
particular attention to the presence of bilateral inspiratory fine crackles as well as the less 
commonly encountered, inspiratory squeaks. In RA patients with known ILD, the physical 
examination should also include assessment for signs and symptoms of pulmonary 
hypertension. 
A 
B 
C
D
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A. Chest radiograph (PA view) showing peripheral interstitial markings, B&C. HRCT showing 
peripheral and lower lobe predominant ground glass opacification and reticulation. 
Fig. 3. RA-ILD mixed cellular and fibrotic  
It is standard of care that newly diagnosed patients with RA should complete a baseline 
screening chest radiograph, especially before the initiation of methotrexate. In most cases, 
particularly in patients with pulmonary risk factors such as smoking, or those who are 
symptomatic with dyspnea and/or cough, a baseline pulmonary function test (PFT), 
including spirometry, lung volumes and diffusion capacity, should also be completed. 
Although evidence-based, formal guidelines are not available, it is considered standard of 
care to also perform a chest radiograph prior to initiation of a biologic therapeutic agent, in 
part to evaluate for stigmata of latent or active tuberculosis, but also to assess for the 
presence of ILD which may be adversely impacted by the therapy (Dixon et al., 2010). In the 
absence of any lung abnormality at time of RA diagnosis, further investigations should be 
guided by clinical context, particularly in preparation for treatment with potentially 
A B
C
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pneumotoxic medications. In the absence of specific evidence-based recommendations with 
regards to radiographic follow-up, clinical judgment should be exercised in making this 
decision.  
Most commonly, ILD in RA is associated with PFT physiologic changes of restriction with a 
decreased diffusing capacity of carbon monoxide (Lee et al., 2005; Pappas et al., 2010). A 
decreased diffusing capacity is the most sensitive parameter for ILD on PFT. This may also 
be the sole PFT abnormality early in the course of ILD. A combination of obstructive and 
restrictive changes may co-exist in patients with other pulmonary co-morbidities such as 
asthma or COPD. As a result, some of these patients may present with combined obstructive 
and restrictive abnormalities or an isolated decreased diffusing capacity. For serial 
monitoring of PFTs, particular attention is paid to changes in absolute and percent predicted 
forced vital capacity (FVC) and diffusing capacity as markers of disease progression and 
response to treatment. A low diffusing capacity has been shown to be associated with 
disease progression and poor outcomes (Biederer et al., 2004, Hakala 1988). Less commonly, 
obstruction, as seen in obliterative bronchiolitis, is the hallmark of diffuse lung disease of 
RA. In this situation, forced expiratory volume in one second (FEV1) is reduced out of 
proportion to FVC, with an FEV1/FVC ratio < 0.8, and there may be hyperinflation and gas 
trapping. As a diagnostic tool, a PFT is insufficient and all RA patients with concern for ILD 
should undergo HRCT. 
The superiority of HRCT over chest radiographs, PFTs, and bronchoalveolar lavage (BAL) 
in identifying ILD has been consistently demonstrated in research studies, although limited 
data exist regarding its exact sensitivity in detecting RA-associated ILD (e.g. Biederer et al., 
2004) . Nevertheless, HRCT is the most sensitive non-invasive modality for the diagnosis of 
ILD in patients with RA. 
The HRCT findings of UIP pattern, particularly in patients with a high pre-test probability 
based on clinical history, physical exam findings and an abnormal PFT, confirms the 
diagnosis of RA-ILD with great confidence (Martinez 2006). This is in part owing to the 
unique radiological features of UIP and it likely being the most common RA-associated 
ILD pattern (Lee et al., 2005). HRCT features of UIP in an RA patient are highly indicative 
of histologic findings of UIP on surgical lung biopsy, but could also be associated with 
fibrotic NSIP. Regardless, the presence of UIP findings unequivocally establishes the 
diagnosis of an ILD. The HRCT findings of NSIP pattern also has high diagnostic value 
albeit to a lesser extent, due to its less specific radiological features (MacDonald et al., 
2001). Radiological uncertainty, inconsistency between diagnostic modalities or with 
clinical presentation, necessitates additional investigations including consideration of a 
surgical lung biopsy.  
Surgical biopsy of lung parenchyma is now commonly performed by video-assisted 
thoracoscopic surgery (VATS). Although surgical risks should always be assessed for the 
individual patient, surgical lung biopsy, particularly VATS biopsy, is a relatively safe 
procedure that is well tolerated (Zhang & Liu, 2010). In light of its safety profile and high 
diagnostic yield, surgical lung biopsy should be strongly considered in the face of 
clinically important diagnostic uncertainty (See Figure 4 for summary of screening and 
diagnosis).  
Bronchoalveolar lavage (BAL), a method to sample the lungs’ terminal airways, 
transbronchial lung biopsy, and radiology-guided needle biopsy, usually provide samples 
that are generally insufficient to adequately characterize or classify ILD (Biederer et al., 
2004). The main role of BAL in immunosuppressed patients with parenchymal 
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Fig. 4. Proposed screening protocol for RA-ILD and diagnosis flowchart 
abnormalities on HRCT is to rule out infection and assess for malignancy. Therefore, unless 
infection is suspected, surgical lung biopsy is the preferred method of histologic detailed 
characterization of RA-associated ILD. 
2.6 Management 
A three-pronged approach should be considered for management of RA patients with ILD. 
The first phase of this approach is education and consideration of transplantation 
evaluation. RA patients diagnosed with ILD need to be counseled about the potentially 
progressive nature of this condition as well as its associated morbidity and mortality. In the 
setting of idiopathic pulmonary fibrosis (IPF), referral for lung transplantation evaluation 
should generally be considered relatively early in the disease course provided that there are 
no obvious contraindications for transplant. Predictors of poor prognosis and the need for 
more rapid assessment for lung transplant include a diffusing capacity less than 39%, 
documented deterioration in FVC by at least 10% or diffusing capacity by at least 15% over 6 
months, new onset exertional oxygen desaturation below 88%, progression of symptoms, or 
advanced disease with evidence of significant honeycombing on HRCT at first presentation 
Abnormal / 
Clinical concern Normal
Monitor pulmonary signs and 
symptoms during routine RA 
follow-up 
HRCT 
PFT’s (if not already done) 
+/- BAL to exclude infection 
ILD diagnosis 
Definitive ILD pattern 
Assess for respiratory signs 
and symptoms 
 
Obtain smoking, occupational 
exposures and medication 
history 
Chest X-ray 
+/- PFTs  
(in the presence of 
symptoms and/or 
pulmonary risk factors 
such as smoking)
Abnormal or 
starting a 
pneumotoxic 
medication 
Indeterminate
Surgical lung biopsy 
RA diagnosis
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(Orens et la., 2006). Although limited data is available for RA associated UIP, an analogous 
approach should be considered since UIP in RA patients seems to carry the same poor 
prognosis as IPF, worse than any other ILD (Park et al., 2007). RA patients with UIP are also 
more likely to experience acute exacerbations (Dawson et al., 2002, Park et al., 2007b), 
analogous to the recently defined acute exacerbations of IPF (Collard et al., 2007), and they 
seem to be less responsive to pharmacological treatments (Nannini et al., 2008). Patients 
with NSIP tend to have a better prognosis, and so transplant evaluation is usually reserved 
for patients with significant progression or more advanced disease that has not responded 
to therapy.  
The second part of management is supportive care. Clinicians should ensure that patients 
receive annual influenza, as well as regular pneumococcal vaccinations. Smoking cessation 
and avoidance of passive smoke exposure are paramount as they exert a deleterious effect 
on disease progression. Assessment of the need for home oxygen should be done in the face 
of worsening respiratory status. For patients with impaired respiratory function, who plan 
to travel by air, clinicians should consider assessing their need for supplemental oxygen at 
altitude even in those who do not meet criteria for oxygen at sea level. Applications for 
disability, handicapped parking, and referrals to patient support groups should be 
implemented early in the management phase. 
Finally, an immunosuppressive treatment regimen should be implemented. Currently, 
clinicians do not have the benefit of evidence-based guidelines to direct the pharmacological 
management of RA-associated ILD and current treatments rely to a great extent on clinical 
experience and evidence from management of ILD in other connective tissue diseases, such 
as scleroderma. In general, the use of glucocorticoids constitutes the basis of 
pharmacological management. However, their efficacy as monotherapy is limited and 
patients would typically require the addition of another immune modulating 
pharmacological agent. Oral prednisone is typically the first component of treatment with a 
starting dose ranging between 0.5 to 1 milligrams per kilogram of body weight daily. 
Patients should then be monitored closely for clinical changes as well as for possible adverse 
effects related to the use of high-dose glucocorticoids. It is prudent to obtain a baseline bone 
mineral density (BMD) and screen patients for the development of diabetes once treatment 
commences. Bone protection therapy with calcium and Vitamin D supplements should be 
given to all patients. Patients with an abnormal BMD at baseline should also be given a 
bisphosphonate. Prophylaxis against pneumocystis pneumonia (PCP) should be employed 
with long term prednisone use of at least 30 mg/day, in particular, if there is concomitant 
use of a cytotoxic agent (Yale & Limper, 1996).  
Serial PFTs and chest HRCT scans are used to objectively assess clinical response to 
treatment. In the absence of clear guidelines as to the frequency of these tests, clinical 
judgment should be exercised. In general, a reasonable approach would be to have the 
initial follow-up at 8 to 12 weeks with repeat PFTs and subsequent follow-up every 3 to 6 
months thereafter. Chest imaging might be initially repeated as early as 6 months after 
initiating immunosuppressive therapy, but typically follow-up imaging is performed 
annually with low-radiation dose CT scans. Repeat imaging should also be considered at 
any time when clinically important or unexplained changes occur in the patient’s clinical 
course. Time to clinical response is variable and while some patients may experience 
improvement within a span of a few weeks, most will require several months, while still 
others may have very limited benefit.  
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A steroid-sparing immunosuppressive agent, should be considered relatively early in cases 
of RA-ILD. Clinical worsening on glucocorticoid monotherapy or significant burden of 
parenchymal involvement, as typically evidenced by >20% involvement on HRCT chest or 
<70% FVC, warrants the addition of a second immunosuppressive agent (Goh et al., 2008). 
Recommendations with respect to the second immunosuppressive agent are derived from 
studies of scleroderma-associated ILD (SSc-ILD). Oral cyclophosphamide, at doses between 
1-2mg/kg body weigh daily, is used for extensive disease although its efficacy may be 
modest at best and its use associated with significant adverse effects. Monthly intravenous 
pulses of cyclophosphamide may be a reasonable alternative to oral cyclophosphamide as it 
has a similar efficacy profile, but lower toxicity when compared to oral therapy (Hoyles et 
al., 2006). Azathioprine can also be used, but may be reserved for patients with less severe 
disease or in those who are intolerant of cyclophosphamide, with an initial dose ranging 
between 2 - 3 milligrams per kilogram daily.  
Various other immune-modulating therapies have been tried for the treatment of RA- ILD, 
none of which is sufficiently supported by empirical data to warrant routine use in practice. 
Application of these therapies to RA-ILD typically stems from clinical experience applying 
these treatments in other CTD-ILD.  
One such example is mycophenolate, which has recently been described in case series to be 
associated with stabilization and potential improvement in lung function in patients with 
CTD-ILD (Saketkoo & Espinoza, 2008; Swigris et al., 2006) and SSc-ILD (Zamora et al., 2008). 
However, one limitation with the use of mycophenolate in the setting of RA is that while it 
might provide lung function benefit, it does not treat joint inflammation, and, therefore, 
often necessitates the use of higher corticosteroid use to manage RA disease activity. Thus, 
we recommend that mycophenolate should be used as a second-line agent in the 
management of RA-ILD. In contrast, methotrexate, a common agent used in many CTD, has 
been shown to not only provide no clinical benefit in RA-ILD, but may be potentially 
harmful by leading to ILD disease progression (Gochuico et al., 2008). Therefore, 
methotrexate should not be used in the setting of RA-ILD. The anti-CD20 antibody, 
Rituximab, has also been suggested based on its use in other CTD- and vasculitis- associated 
lung involvement (Brulhart et al., 2006, Stasi et al., 2006). However, caution is advised in 
light of concerns raised over the risk of pneumonitis with rituximab (Leon et al., 2004), 
including specifically in RA-ILD patients (Jadon et al., 2008). Anti-TNF alpha antibodies, 
tyrosine-kinase inhibitors (Distler et al., 2008) and anti-IL6 receptor antibody are also being 
considered for RA-associated ILD, but data is very limited and their safety in this setting has 
not been confidently established. The use of other agents, such as cyclosporine and 
hydroxychloroquine, has also been suggested yet with very limited empirical evidence 
(Chang et al., 2002).  
Patients presenting with severe clinical symptoms, particularly with evidence of AIP, may 
receive an initial course of intravenous methylprednisolone pulses at 7 to 10 milligrams per 
kilogram of body weight. Intravenous cyclophosphamide at 10 to 15 milligrams per 
kilogram can be initiated concomitantly in this setting if no other contraindications exist 
(Kelly & Saravanan 2008). Once clinically stable, patients should then be switched to oral 
therapy.  
Several adjuvant therapies have been suggested for RA- ILD, extrapolated from practices 
used to treat idiopathic or other CTD subtypes with ILD. One such treatment is N-
acetylcysteine (NAC), which is commonly used in patients with idiopathic pulmonary 
fibrosis (IPF). It is believed to exert an anti-oxidant effect as well as have mucolytic 
www.intechopen.com
 Rheumatoid Arthritis Interstitial Lung Disease 
 
77 
properties. While limited evidence supports its efficacy in patients with IPF (Demedts et al., 
2005), there is currently no evidence-based rationale for its use in RA- ILD. The use of 
anticoagulation in patients with RA- ILD has also been suggested in light of the increased 
risk of thrombosis associated with IPF (Hubbard et al., 2008). In the absence of empirical 
evidence, the decision to use anticoagulation should be made based on clinical risk 
assessment of each patient’s individual risk factors and should not be initiated without 
direct guidance from a transplant centre in a patient being considered for lung 
transplantation.  
3. Pulmonary inflammation and the pathogenesis of RA 
RA has traditionally been conceptualized as an autoimmune disease of the synovium 
associated with an inappropriate excessive inflammatory response leading to systemic 
complications. Although the exact etiology of RA remains to be elucidated, it is now evident 
that RA’s underlying pathophysiology is far more complex and extends beyond the 
traditional view that the disease begins in the synovium. Growing evidence suggest that the 
systemic inflammatory response and antibody formation precede synovial involvement and 
clinical symptoms of RA (van de Sande et al., 2011). In fact, antibodies associated with RA, 
including IgM rheumatoid factor and anti-citrullinated protein antibodies (ACPA) (a.k.a. 
anti-cyclic citrullinated protein, anti-CCP, antibodies) appear to be present in the serum of 
RA patients many years before the onset of clinical disease (Nielen et al., 2004, Rantapää-
Dahlqvist et al., 2003).  
The key to understanding the immunological processes believed to underlie the 
development of RA is the concept of citrullination. This refers to the post-translational 
modification of proteins whereby the amino acid arginine is de-aminated and converted to 
citrulline by the enzyme peptidylarginine deiminas (PAD) (Yamada et al., 2005). This 
conversion occurs intracellularly to affect the electrical charge of the protein, thereby 
altering its folding. In order to develop antibodies to citrullinated peptides, the immune 
system must be exposed to these altered proteins, which occurs following cell death, often 
incited by insult to the cell wall such as in the context of inflammation. The identity of 
citrullinated autoantigens is increasingly known, with the leading candidates for the 
development of RA being alpha-enolase, filaggren, and vimentin (Schellekens et al., 2000, 
van Venrooij WJ et al., 2008). Although it has been hypothesized that the primary tissue site 
of citrullination for development of RA is the joint (synovium), it is becoming increasingly 
recognized that other tissue sites may be involved in the pathogenesis of RA including the 
lung and oral mucosa (Bingham et al., 2010, Bongartz et al., 2007). In this section, we will 
highlight the mechanisms of how development of autoimmunity and RA is not restricted to 
processes in the joint and how pulmonary inflammation may incite the development of RA. 
3.1 Genetic risk of pulmonary disease and of RA 
Genetics is known to play an important role in the development of RA and its contribution 
is estimated to be around 30% and, in some studies, up to 60% (MacGregor et al., 2000). The 
strongest genetic association with RA has been mapped to a gene area on chromosome 6 
known as the Human Leukocyte Antigen (HLA) locus (a.k.a. Major Histocompatibility 
Complex, MHC (Zanelli et al., 2000). These genes encode various proteins that play 
important immunological roles, including in the key distinction of self from foreign. Among 
the HLA loci, the HLA-DRB1 alleles have been shown to have strong association with RA 
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(Zanelli et al., 2000), although emerging data now also point to other loci, particularly HLA–
DPB1, as independently conferring increased risk for ACPA-positive RA (Ding et al., 2009).  
Common to the multiple HLA-DRB1 alleles found to be associated with RA, is a shared 
amino-acid sequence, or motif, which was thus named the ‘shared epitope’ (SE) (Gregersen 
et al., 1987). The presence of SE alleles is known to be strongly associated with susceptibility 
to RA (du Montcel et al., 2005) and the presence of ACPA (Van der Helm-van Mil et al., 
2006). The association between SE alleles and RA has been found to be significantly 
influenced by smoking, particularly, though not exclusively, in the presence of ACPA 
(Padyukov et al., 2004). Recent evidence suggests that the association between smoking and 
increased risk of ACPA-positive RA with SE alleles is dose-dependent, where individuals 
with over 20 pack-year smoking history have a 40 times increased risk of ACPA-positive RA 
if they carry the double SE alleles compared to non-smokers without the SE alleles (Källberg 
et al., 2011). 
Finally, of note, existing evidence also suggest that certain other HLA-DR alleles, 
particularly HLA-DR4, are associated with the development of lung disease in RA patients, 
independent of smoking (Scott et al., 1987).  
3.2 Importance of auto-antibodies to citrullinated peptides 
In addition to being an apparent predictive marker for the development of RA, the presence 
of ACPA in patients also appear to be associated with a greater risk of developing extra-
articular manifestations, including specifically lung serositis and pulmonary fibrosis 
(Alexiou et al., 2008, Turesson et al., 2007). Moreover, a recent study by Bongartz et al., 
(2007) included immunohistochemical examination of lung biopsies from 18 patients with 
RA-ILD and revealed the presence of citrullinated proteins in 8 (44%) of these patients 
(Bongartz et al., 2007). The exact identity of the citrullinated autoantigen was not identified; 
moreover, citrullination did not show any significant association with factors such as 
smoking, disease severity, histological subtype, degree of inflammation, or steroid use 
(Bongartz et al., 2007). The findings of citrullinated proteins in lung samples from non-RA 
patients with idiopathic ILD in the same study suggest that this process is not unique to RA 
and likely reflects a non-specific response to tissue injury and inflammation. The key 
difference, therefore, lies in the fact that, in RA patients, an aberrant immune response 
occurs by which ACPA are generated in response to these proteins, which in turn result in 
pathology. The challenge is then to identify the potential factors that might mediate this 
aberrant process. 
3.3 Environmental triggers of pulmonary inflammation 
Smoking has been firmly established as a causative agent in lung inflammation and injury. It 
has also been shown to be associated with both the development of RA, accounting for 
nearly 20% of the risk, and worse disease course of RA, even years after smoking cessation 
(Albano et al., 2001, Harrison, 2002). These two seemingly unrelated adverse effects of 
smoking on lung and RA are in fact intricately connected beyond the mere aggravated 
inflammatory response triggered by smoking. Smoking has been shown to be associated 
with an increase in pulmonary protein citrullination, which appears to be mediated by 
increase in PAD enzyme expression, particularly PAD2, in both parenchymal and bronchial 
tissue (Makrygiannakis et al., 2008). Moreover, as outlined previously (see section 3.1 
Genetic risk of pulmonary disease and of RA) a strong, dose-dependent, association has 
been established between smoking and the presence of ACPA in RA patients (Källberg, et 
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al., 2011). These findings point to a possible pathogenesis of pulmonary inflammation in RA 
patients in which ACPA react with the increased presence of citrullinated proteins in 
pulmonary tissue that were the result of pulmonary injury caused by environmental trigger 
such as smoking. Similar pathogenic processes were found with other environmental 
exposures such as silica (Stolt et al., 2010). 
However, current evidence suggests that the interplay between synovium and lung is in fact 
far more complex. The findings of ACPA in ILD patients without clinical evidence of 
articular symptoms suggest that these antibodies can be generated independent of synovial 
involvement. This was further corroborated by a prospective study of ACPA-positive 
patients, who were found to have no radiological or histological evidence of synovial 
inflammation (van de Sande et al., 2011). In this study, 13 patients with positive RA serology 
(IgM rheumatoid factor and/or ACPA) but without clinical evidence of arthritis underwent 
knee MRI and arthroscopic synovial tissue biopsy with immuno-histochemistry testing. No 
significant differences were found when the results were compared to those obtained from a 
group of individuals with negative RA serology. After a median follow-up period of 3 
months (range 1-6 months), 4 of these patients developed clinical evidence of arthritis. This 
demonstrated that the synovium in ACPA-positive patients is initially normal, even in 
patients who later develop clinical arthritis. In addition, existing evidence suggests that a 
proportion of patients with positive RA serology may already have HRCT parenchymal 
lung changes at time of RA diagnosis (Gabbay et al., 1997, Metafratzi et al., 2007, 
Reynsdottir et al., 2011). In fact, a retrospective study by Gizinski et al. (2009) showed that 
positive RA serology can be found in smokers with ILD without symptoms and signs of RA, 
but who may later develop RA. Therefore, clinicians assessing patients with positive RA 
serology but no articular symptoms should nevertheless inquire and be mindful of 
respiratory symptoms in these patients. 
Taken together, these findings evoke a conceptual paradigm different from the long-held 
view of pulmonary inflammation being an extra-articular manifestation of synovial 
inflammation. In this paradigm, synovial inflammation is seen as a down-stream 
consequence of an aberrant immunological pulmonary process triggered by insults, such as 
smoking, that lead to the formation of ACPA. The ACPA, in turn, react to citrullinated 
proteins formed in the synovium due to a different, independent, insult such as mechanical 
or infectious joint injury (See figure 5). Further research is needed and is underway to 
elucidate this intricate interplay between the lung and the synovium as well as the 
possibility that such an interaction with the synovium may not only be limited to the lung. 
3.4 Pre-RA and its clinical implications 
The concept of ‘early RA’ has long been clinically utilized to denote patients in the early 
stages of the disease. However, the synovium of patients with ‘early RA’ already displays 
radiological (van der Heijde, 1995) and histological (Tak, 2001) evidence of chronic 
inflammation. Therefore, the concept of ‘pre-RA’ has been suggested to describe the time 
period before the onset of clinical signs and symptoms of synovial inflammation (van de 
Sande et al., 2011). During this time, patients may already have evidence of sub-clinical 
systemic inflammation, such as elevated non-specific inflammatory markers (e.g. C-reactive 
protein), and may be tested positive for the presence of ACPA. As previously described, the 
presence of ACPA can occur in the absence of synovial inflammation and may, in fact, 
precede clinical manifestation of arthritis by longer than a decade (Nielen et al., 2004). It is 
presumably during this time interval that the second, independent, injury occurs, which 
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Fig. 5. The postulated interaction between genetics, environmental factors, pulmonary 
inflammation and protein citrullination in the pathogenesis of RA 
leads to synovial protein citrullination and the resulting epitope spreading and 
development of synovial inflammation.  
This multi-factorial model of RA development raises the potential for prevention, which 
may be aimed at averting, slowing, or potentially reversing the progression towards clinical 
RA. The first and foremost preventative measure based on the available evidence is 
avoidance of tobacco smoking. Since environmental exposures, such as smoking and silica 
inhalation, appear to play a key role in the initial formation of ACPA, avoidance of these 
triggers may potentially abort the development of RA in genetically susceptible individuals. 
Further research is necessary to better understand the initial development of ACPA and 
explore the potential for prevention, particularly in genetically susceptible individuals. The 
existence of a ‘pre-RA’ stage also provides an opportunity for potential pharmacological 
interventions that might prevent or delay the development of synovial inflammation. The 
identification of the second event that results in synovial protein citrullination should also 
be a focus of future research and preventative efforts.  
The emerging evidence of the close interplay between the lungs and the synovium together 
with the growing recognition of the clinical significance of pulmonary complications in RA 
patients, including RA-ILD, suggest that RA patients may benefit from a multidisciplinary 
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approach to their management. Although such collaboration appears to be most beneficial 
to RA patients with pulmonary complications, it may expand in the future to include 
patients with pulmonary inflammation at risk of RA by virtue of their genetics or ACPA 
presence, without yet having any articular manifestations.  
4. Summary 
Our understanding of RA and RA-ILD is quickly evolving in light of ongoing research. RA-
ILD is increasingly recognized as a prevalent clinical entity with significant associated 
morbidity and mortality, which poses both diagnostic and therapeutic challenges to 
clinicians and calls for increased attention to pulmonary abnormalities in RA patients. In 
addition, as highlighted in this chapter, growing evidence also suggests that pulmonary 
inflammation plays an important role in the etiology of RA, particularly in autoantibody-
positive patients, with evidence of lung injury preceding synovial inflammation. The 
complex interplay between the lung and the synovium remains to be further elucidated but 
it is clear that synovial inflammation can no longer be viewed as an isolated, independent 
process. The likely multi-factorial nature of this interplay not only raises the potential for 
new therapeutics targets in RA, but also raises the prospect for prevention. Furthermore, it 
also raises the question of whether similar complex interactions exist between the synovium 
and other organs. Future research is currently underway and would hopefully provide 
answers to these important questions, leading to a better understanding and management of 
RA. 
5. Key points 
1. RA is a common systemic inflammatory disorder affecting 1% of the general population 
2. RA-ILD is a serious extra-articular manifestation that confers significant morbidity and 
mortality 
3. Clinicians need to be vigilant to screen for respiratory signs and symptoms in RA 
patients as these may represent an underlying ILD 
4. The diagnosis of RA-ILD can be made with HRCT but, in some cases, diagnostic 
uncertainty necessitates a surgical lung biopsy 
5. UIP and NSIP are the most common histopathological patterns of RA-ILD 
6. The treatment of RA-ILD is three-pronged, including education and transplant 
evaluation, supportive care and the use of immunosuppressive medications 
7. Pulmonary inflammation, protein citrullination and the formation of auto-antibodies to 
citrullinated peptides may play a key role in the pathogenesis of RA 
8. The interaction of genetics and environmental factors is fundamental to this process 
9. Growing evidence point to a complex, multi-factorial interaction between the lung and 
the synovium, with lung injury preceding synovial inflammation 
10. Further research is necessary to delineate this complex interplay and explore its clinical 
implications 
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